The most important clinical problem associated with cancer therapy using VEGF- or VEFGR-targeting agents is drug resistance, as a result of clonal expansion or subclonal evolution of tumors with the upregulation of other angiogenic factors, such as FGF2 (15,25). Here, VEGFA is linked to cancer.